


























- Roychoudhury, S., Anderson, K. M., Ye, J., & Mukhopadhyay, P.
(2021). Robust design and analysis of clinical trials with
nonproportional hazards: A straw man guidance from a cross-pharma
working group. *Statistics in Biopharmaceutical Research*, 1–15.

- Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T.,
Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020).
Alternative analysis methods for time to event endpoints under
nonproportional hazards: A comparative analysis. *Statistics in
Biopharmaceutical Research*, *12*(2), 187–198.

- Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., &
Wei, L. (2020). On the empirical choice of the time window for
restricted mean survival time. *Biometrics*, *76*(4), 1157–1166.

- Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K.,
Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A.,
Dwyer, J. P., et al. (2018). Effect of lorcaserin on prevention and
remission of type 2 diabetes in overweight and obese patients
(CAMELLIA-TIMI 61): A randomised, placebo-controlled trial. *The
Lancet*, *392*(10161), 2269–2279.

- Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J.,
Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O.,
Robert, C., et al. (2018). Baseline tumor size is an independent
prognostic factor for overall survival in patients with melanoma treated
with Pembrolizumab. *Clinical Cancer Research*, *24*(20), 4960–4967.

- Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G.,
Garon, E. B., Riess, J. W., Jain, L., Mayawala, K., Kang, J.,
Ebbinghaus, S. W., et al. (2018). Pembrolizumab exposure–response
assessments challenged by association of cancer cachexia and catabolic
ClearancePembrolizumab PK/PD confounding and cancer cachexia. *Clinical
Cancer Research*, *24*(23), 5841–5849.

- Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., Joshua, A. M.,
Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Hwu, W.-J.,
Kefford, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P.,
Perrone, A. M., Kang, S. P., Ebbinghaus, S., Anderson, K. M., &
Gangadhar, T. C. (2014). Baseline tumor size as an independent
prognostic factor for overall survival in patients with metastatic
melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
*Journal of Clinical Oncology*, *32*(15\_suppl), 3015–3015.

- Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein,
C., Dudinak, J., Fardipour, P., Gallo, P., Givens, S., Lewis, R., et al.
(2009). Good practices for adaptive clinical trials in pharmaceutical
product development. *Drug Information Journal*, *43*(5), 539–556.

- Liu, Q., & Anderson, K. M. (2008). On adaptive extensions of group
sequential trials for clinical investigations. *Journal of the American
Statistical Association*, *103*(484), 1621–1630.

- Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson,
K. M., Daifotis, A. G., & Gann, P. H. (2007). Detection bias due to the
effect of finasteride on prostate volume: A modeling approach for
analysis of the Prostate Cancer Prevention Trial. *Journal of the
National Cancer Institute*, *99*(18), 1366–1374.

- Chuang-Stein, C., Anderson, K., Gallo, P., & Collins, S. (2006).
Sample size reestimation: A review and recommendations. *Drug
Information Journal*, *40*(4), 475–484.

- Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., &
Pinheiro, J. (2006). Adaptive designs in clinical drug development—an
executive summary of the PhRMA working group. *Journal of
Biopharmaceutical Statistics*, *16*(3), 275–283.

- Antman, E. M., Cooper, H., Gibson, C., Lemos, J. A. de, McCabe, C.,
Giugliano, R., Coussement, P., Murphy, S., Scherer, J., Anderson, K., et
al. (2002). Determinants of improvement in epicardial flow and
myocardial perfusion for ST elevation myocardial infarction. Insights
from TIMI 14 and InTIME-II. *European Heart Journal*, *23*(12), 928–933.

- Akkerhuis, K. M., Deckers, J. W., Lincoff, A. M., Tcheng, J. E.,
Boersma, E., Anderson, K., Balog, C., Califf, R. M., Topol, E. J., &
Simoons, M. L. (2001). Risk of stroke associated with abciximab among
patients undergoing percutaneous coronary intervention. *JAMA*,
*286*(1), 78–82.

- Anderson, K. M., Califf, R. M., Stone, G. W., Neumann, F.-J.,
Montalescot, G., Miller, D. P., Ferguson, J. J., Willerson, J. T.,
Weisman, H. F., & Topol, E. J. (2001). Long-term mortality benefit with
abciximab in patients undergoing percutaneous coronary intervention.
*Journal of the American College of Cardiology*, *37*(8), 2059–2065.

- Antman, E. M., Gibson, C., Lemos, J. A. de, Giugliano, R., McCabe,
C., Coussement, P., Menown, I., Nienaber, C., Rehders, T., Frey, M., et
al. (2000). Combination reperfusion therapy with abciximab and reduced
dose reteplase: Results from TIMI 14. *European Heart Journal*,
*21*(23), 1944–1953.

- Lemos, J. A. de, Antman, E. M., Gibson, C. M., McCabe, C. H.,
Giugliano, R. P., Murphy, S. A., Coulter, S. A., Anderson, K., Scherer,
J., Frey, M. J., et al. (2000). Abciximab improves both epicardial flow
and myocardial reperfusion in ST-elevation myocardial infarction:
Observations from the TIMI 14 trial. *Circulation*, *101*(3), 239–243.

- The Abciximab in Ischemic Stroke Investigators. (2000). Abciximab
in acute ischemic stroke: A randomized, double-blind,
placebo-controlled, dose-escalation study. *Stroke*, *31*(3), 601–609.

- Kereiakes, D. J., Berkowitz, S. D., Lincoff, A. M., Tcheng, J. E.,
Wolski, K., Achenbach, R., Melsheimer, R., Anderson, K., Califf, R. M.,
& Topol, E. J. (2000). Clinical correlates and course of
thrombocytopenia during percutaneous coronary intervention in the era of
abciximab platelet glycoprotein IIb/IIIa blockade. *American Heart
Journal*, *140*(1), 74–80.

- Lincoff, A. M., Mark, D. B., Tcheng, J. E., Califf, R. M., Bala, M.
V., Anderson, K. M., Davidson-Ray, L., Knight, J. D., Cabot, C. F., &
Topol, E. J. (2000). Economic assessment of platelet glycoprotein
IIb/IIIa receptor blockade with abciximab and low-dose heparin during
percutaneous coronary revascularization: Results from the EPILOG
randomized trial. *Circulation*, *102*(24), 2923–2929.

- Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H.,
Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. J., Menown, I.,
Rupprecht, H.-J., et al. (1999). Abciximab facilitates the rate and
extent of thrombolysis: Results of the thrombolysis in myocardial
infarction (TIMI) 14 trial. *Circulation*, *99*(21), 2720–2732.

- Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J.,
Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C.,
Cabot, C. F., et al. (1999). Sustained suppression of ischemic
complications of coronary intervention by platelet GP IIb/IIIa blockade
with abciximab: One-year outcome in the EPILOG trial. *Circulation*,
*99*(15), 1951–1958.

- Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J.,
Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C. F., et al.
(1999). Outcomes at 1 year and economic implications of platelet
glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting:
Results from a multicentre randomised trial. *The Lancet*, *354*(9195),
2019–2024.

- Antman, E., Giugliano, R., McCabe, C., Gibson, M., Adgey, A.,
Ghali, M., Coussement, P., Anderson, K., Scherer, J., Van de Werf, F.,
et al. (1998). Abciximab (ReoPro) potentiates thrombolysis in ST
elevation myocardial infarction: Results of TIMI 14 trial. *Journal of
the American College of Cardiology*, *31*(2SA), 191A–191A.

- Kereiakes, D. J., Lincoff, A. M., Miller, D. P., Tcheng, J. E.,
Cabot, C. F., Anderson, K. M., Weisman, H. F., Califf, R. M., & Topol,
E. J. (1998). Abciximab therapy and unplanned coronary stent deployment:
Favorable effects on stent use, clinical outcomes, and bleeding
complications. *Circulation*, *97*(9), 857–864.

- Kleiman, N. S., Lincoff, A. M., Kereiakes, D. J., Miller, D. P.,
Aguirre, F. V., Anderson, K. M., Weisman, H. F., Califf, R. M., & Topol,
E. J. (1998). Diabetes mellitus, glycoprotein IIb/IIIa blockade, and
heparin: Evidence for a complex interaction in a multicenter trial.
*Circulation*, *97*(19), 1912–1920.

- CAPTURE Investigators and others. (1997). Randomized
placebo-controlled trial of abciximab before and during coronary
intervention in refractory angina: The CAPTURE study. *Lancet*, *349*,
1429–1435.

- The EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa
receptor blockade and low-dose heparin during percutaneous coronary
revascularization. *New England Journal of Medicine*, *336*(24),
1689–1697.

- Lincoff, A. M., Califf, R. M., Anderson, K. M., Weisman, H. F.,
Aguirre, F. V., Kleiman, N. S., Harrington, R. A., Topol, E. J., &
investigators, E. (1997). Evidence for prevention of death and
myocardial infarction with platelet membrane glycoprotein IIb/IIIa
receptor blockade by abciximab (<span class="nocase">c7E3 Fab</span>)
among patients with unstable angina undergoing percutaneous coronary
revascularization. *Journal of the American College of Cardiology*,
*30*(1), 149–156.

- Lincoff, A. M., Tcheng, J. E., Califf, R. M., Bass, T., Popma, J.
J., Teirstein, P. S., Kleiman, N. S., Hattel, L. J., Anderson, H. V.,
Ferguson, J. J., et al. (1997). Standard versus low-dose weight-adjusted
heparin in patients treated with the platelet glycoprotein IIb/IIIa
receptor antibody fragment abciximab (<span class="nocase">c7E3
Fab</span>) during percutaneous coronary revascularization. *The
American Journal of Cardiology*, *79*(3), 286–291.

- Mak, K.-H., Challapalli, R., Eisenberg, M. J., Anderson, K. M.,
Califf, R. M., Topol, E. J., investigators, E., et al. (1997). Effect of
platelet glycoprotein IIb/IIIa receptor inhibition on distal
embolization during percutaneous revascularization of aortocoronary
saphenous vein grafts. *The American Journal of Cardiology*, *80*(8),
985–988.

- Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E.,
Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D.
P., Anderson, K. M., et al. (1997). Long-term protection from myocardial
ischemic events in a randomized trial of brief integrin *β*<!-- -->3
blockade with percutaneous coronary intervention. *JAMA*, *278*(6),
479–484.

- Coller, B. S., Anderson, K. M., & Weisman, H. F. (1996). The
anti-GPIIb-IIIa agents: Fundamental and clinical aspects.
*Pathophysiology of Haemostasis and Thrombosis*, *26*(Suppl. 4),
285–293.

- Lefkovits, J., Ivanhoe, R. J., Califf, R. M., Bergelson, B. A.,
Anderson, K. M., Stoner, G. L., Weisman, H. F., Topol, E. J.,
Investigators, G. E., et al. (1996). Effects of platelet glycoprotein
IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab)
on acute and six-month outcomes after percutaneous transluminal coronary
angioplasty for acute myocardial infarction. *The American Journal of
Cardiology*, *77*(12), 1045–1051.

- Mark, D. B., Talley, J. D., Topol, E. J., Bowman, L., Lam, L. C.,
Anderson, K. M., Jollis, J. G., Cleman, M. W., Lee, K. L., Aversano, T.,
et al. (1996). Economic assessment of platelet glycoprotein IIb/IIIa
inhibition for prevention of ischemic complications of high-risk
coronary angioplasty. *Circulation*, *94*(4), 629–635.

- Aguirre, F. V., Topol, E. J., Ferguson, J. J., Anderson, K.,
Blankenship, J. C., Heuser, R. R., Sigmon, K., Taylor, M., Gottlieb, R.,
Hanovich, G., et al. (1995). Bleeding complications with the chimeric
antibody to platelet glycoprotein IIb/IIIa integrin in patients
undergoing percutaneous coronary intervention. *Circulation*, *91*(12),
2882–2890.

- Coller, B. S., Anderson, K., & Weisman, H. F. (1995). New
antiplatelet agents: Platelet GPIIb/IIIa antagonists. *Thrombosis and
Haemostasis*, *74*(07), 302–308.

- Moliterno, D. J., Califf, R. M., Aguirre, F. V., Anderson, K.,
Sigmon, K. N., Weisman, H. F., Topol, E. J., EPIC Study Investigators,
et al. (1995). Effect of platelet glycoprotein IIb/IIIa integrin
blockade on activated clotting time during percutaneous transluminal
coronary angioplasty or directional atherectomy (the EPIC trial). *The
American Journal of Cardiology*, *75*(8), 559–562.

- Cole, B. F., Gelber, R. D., & Anderson, K. M. (1994). Parametric
approaches to quality-adjusted survival analysis. *Biometrics*, 621–631.

- The EPIC Investigators. (1994). Use of a monoclonal antibody
directed against the platelet glycoprotein IIb/IIIa receptor in
high-risk coronary angioplasty. *New England Journal of Medicine*,
*330*(14), 956–961.

- Lauer, M. S., Anderson, K. M., Larson, M. G., & Levy, D. (1994). A
new method for indexing left ventricular mass for differences in body
size. *The American Journal of Cardiology*, *74*(5), 487–491.

- Odell, P. M., Anderson, K. M., & Kannel, W. B. (1994). New models
for predicting cardiovascular events. *Journal of Clinical
Epidemiology*, *47*(6), 583–592.

- Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley,
S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994).
Randomised trial of coronary intervention with antibody against platelet
IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six
months. *The Lancet*, *343*(8902), 881–886.

- Wilson, P. W., Anderson, K. M., Harri, T., Kannel, W. B., &
Castelli, W. P. (1994). Determinants of change in total cholesterol and
HDL-C with age: The framingham study. *Journal of Gerontology*, *49*(6),
M252–M257.

- Ellis, S. G., Tcheng, J. E., Navetta, F. I., Muller, D., Weisman,
H. F., Smith, C., Anderson, K. M., Califf, R. M., & Topol, E. J. (1993).
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab
directed against platelet glycoprotein IIb/IIIa in patients undergoing
elective coronary angioplasty. *Coronary Artery Disease*, *4*(2),
167–175.

- Ho, K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D.
(1993). Survival after the onset of congestive heart failure in
framingham heart study subjects. *Circulation*, *88*(1), 107–115.

- Anderson, K. M., & Kannel, W. B. (1992). Obesity and disease. In P.
Björntorp & B. Brodoff (Eds.), *Obesity* (pp. 465–473). JB Lippincott
Company.

- Benjamin, E. J., Levy, D., Anderson, K. M., Wolf, P. A., Plehn, J.
F., Evans, J. C., Comai, K., Fuller, D. L., & Sutton, M. S. J. (1992).
Determinants of doppler indexes of left ventricular diastolic function
in normal subjects (the framingham heart study). *The American Journal
of Cardiology*, *70*(4), 508–515.

- Berger, C. J., Murabito, J. M., Evans, J. C., Anderson, K. M., &
Levy, D. (1992). Prognosis after first myocardial infarction: Comparison
of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart
Study. *JAMA*, *268*(12), 1545–1551.

- Castelli, W. P., Anderson, K., Wilson, P. W., & Levy, D. (1992).
Lipids and risk of coronary heart disease the framingham study. *Annals
of Epidemiology*, *2*(1-2), 23–28.

- Genest Jr, J., McNamara, J. R., Ordovas, J. M., Jenner, J. L.,
Silberman, S. R., Anderson, K. M., Wilson, P. W., Salem, D. N., &
Schaefer, E. J. (1992). Lipoprotein cholesterol, apolipoprotein A-I and
B and lipoprotein (a) abnormalities in men with premature coronary
artery disease. *Journal of the American College of Cardiology*,
*19*(4), 792–802.

- Kannel, W. B., Anderson, K., & Wilson, P. W. (1992). White blood
cell count and cardiovascular disease: Insights from the framingham
study. *JAMA*, *267*(9), 1253–1256.

- Kreger, B. E., Anderson, K. M., Schatzkin, A., & Splansky, G. L.
(1992). Serum cholesterol level, body mass index, and the risk of colon
cancer. The framingham study. *Cancer*, *70*(5), 1038–1043.

- Lauer, M. S., Anderson, K. M., & Levy, D. (1992). Separate and
joint influences of obesity and mild hypertension on left ventricular
mass and geometry: The framingham heart study. *Journal of the American
College of Cardiology*, *19*(1), 130–134.

- Lauer, M. S., Levy, D., Anderson, K. M., & Plehn, J. F. (1992). Is
there a relationship between exercise systolic blood pressure response
and left ventricular mass? The framingham heart study. *Annals of
Internal Medicine*, *116*(3), 203–210.

- Levy, D., Murabito, J. M., Anderson, K. M., Christiansen, J. C., &
Castelli, W. P. (1992). Echocardiographic left ventricular hypertrophy:
Clinical characteristics. The framingham heart study. *Clinical and
Experimental Hypertension. Part A: Theory and Practice*, *14*(1-2),
85–97.

- O’Leary, D. H., Anderson, K. M., Wolf, P. A., Evans, J. C., &
Poehlman, H. W. (1992). Cholesterol and carotid atherosclerosis in older
persons: The framingham study. *Annals of Epidemiology*, *2*(1-2),
147–153.

- Odell, P. M., Anderson, K. M., & D’Agostino, R. B. (1992). Maximum
likelihood estimation for interval-censored data using a Weibull-based
accelerated failure time model. *Biometrics*, 951–959.

- Singer, D. E., Nathan, D. M., Anderson, K. M., Wilson, P. W., &
Evans, J. C. (1992). Association of *H**b**A*<sub>1*c*</sub> with
prevalent cardiovascular disease in the original cohort of the
framingham heart study. *Diabetes*, *41*(2), 202–208.

- Anderson, K. M., Odell, P. M., Wilson, P. W., & Kannel, W. B.
(1991). Cardiovascular disease risk profiles. *American Heart Journal*,
*121*(1), 293–298.

- Anderson, K. M. (1991). A nonproportional hazards weibull
accelerated failure time regression model. *Biometrics*, 281–288.

- Anderson, K. M., Wilson, P., Odell, P. M., & Kannel, W. B. (1991).
An updated coronary risk profile. A statement for health professionals.
*Circulation*, *83*(1), 356–362.

- Galderisi, M., Anderson, K. M., Wilson, P. W., & Levy, D. (1991).
Echocardiographic evidence for the existence of a distinct diabetic
cardiomyopathy (the framingham heart study). *The American Journal of
Cardiology*, *68*(1), 85–89.

- Goldberg, R. J., Bengtson, J., Chen, Z., Anderson, K. M., Locati,
E., & Levy, D. (1991). Duration of the QT interval and total and
cardiovascular mortality in healthy persons (the framingham heart study
experience). *The American Journal of Cardiology*, *67*(1), 55–58.

- Lauer, M. S., Anderson, K. M., Kannel, W. B., & Levy, D. (1991).
The impact of obesity on left ventricular mass and geometry: The
framingham heart study. *JAMA*, *266*(2), 231–236.

- Lauer, M. S., Anderson, K. M., & Levy, D. (1991). Influence of
contemporary versus 30-year blood pressure levels on left ventricular
mass and geometry: The framingham heart study. *Journal of the American
College of Cardiology*, *18*(5), 1287–1294.

- Okin, P. M., Anderson, K., Levy, D., & Kligfield, P. (1991). Heart
rate adjustment of exercise-induced ST segment depression. Improved risk
stratification in the framingham offspring study. *Circulation*,
*83*(3), 866–874.

- Silberfarb, P. M., Anderson, K. M., Rundle, A. C., Holland, J.,
Cooper, M. R., & McIntyre, O. (1991). Mood and clinical status in
patients with multiple myeloma. *Journal of Clinical Oncology*, *9*(12),
2219–2224.

- Wilson, P. W., Anderson, K. M., Castelli, W. P., & Kannel, W. B.
(1991). Twelve-year incidence of coronary heart disease in middle-aged
adults during the era of hypertensive therapy: The framingham offspring
study. *The American Journal of Medicine*, *90*(1), 11–16.

- Ballard-Barbash, R., Schatzkin, A., Carter, C. L., Kannel, W. B.,
Kreger, B. E., D’Agostino, R. B., Splansky, G. L., Anderson, K. M., &
Helsel, W. E. (1990). Body fat distribution and breast cancer in the
framingham study. *JNCI: Journal of the National Cancer Institute*,
*82*(4), 286–290.

- Ballard-Barbash, R., Schatzkin, A., Albanes, D., Schiffman, M. H.,
Kreger, B. E., Kannel, W. B., Anderson, K. M., & Helsel, W. E. (1990).
Physical activity and risk of large bowel cancer in the framingham
study. *Cancer Research*, *50*(12), 3610–3613.

- D’Agostino, R. B., Lee, M.-L., Belanger, A. J., Cupples, L. A.,
Anderson, K., & Kannel, W. B. (1990). Relation of pooled logistic
regression to time dependent cox regression analysis: The framingham
heart study. *Statistics in Medicine*, *9*(12), 1501–1515.

- Jones, M. G., Anderson, K. M., Wilson, P. W., Kannel, W. B.,
Wagner, N. B., & Wagner, G. S. (1990). Prognostic use of a QRS scoring
system after hospital discharge for initial acute myocardial infarction
in the framingham cohort. *The American Journal of Cardiology*, *66*(5),
546–550.

- Kaufman, H. W., McNamara, J. R., Anderson, K. M., Wilson, P. W., &
Schaefer, E. J. (1990). How reliably can compact chemistry analyzers
measure lipids? *JAMA*, *263*(9), 1245–1249.

- Levy, D., Labib, S. B., Anderson, K. M., Christiansen, J. C.,
Kannel, W. B., & Castelli, W. P. (1990). Determinants of sensitivity and
specificity of electrocardiographic criteria for left ventricular
hypertrophy. *Circulation*, *81*(3), 815–820.

- Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., &
Castelli, W. P. (1990). Prognostic implications of echocardiographically
determined left ventricular mass in the framingham heart study. *New
England Journal of Medicine*, *322*(22), 1561–1566.

- Levy, D., Wilson, P. W., Anderson, K. M., & Castelli, W. P. (1990).
Stratifying the patient at risk from coronary disease: New insights from
the framingham heart study. *American Heart Journal*, *119*(3), 712–717.

- Murabito, J. M., Anderson, K. M., Kannel, W. B., Evans, J. C., &
Levy, D. (1990). Risk of coronary heart disease in subjects with chest
discomfort: The framingham heart study. *The American Journal of
Medicine*, *89*(3), 297–302.

- Castelli, W. P., Wilson, P. W., Levy, D., & Anderson, K. (1989).
Cardiovascular risk factors in the elderly. *The American Journal of
Cardiology*, *63*(16), 12–19.

- Kreger, B. E., Anderson, K. M., & Kannel, W. B. (1989). Prevalence
of intraventricular block in the general population: The framingham
study. *American Heart Journal*, *117*(4), 903–910.

- Preisler, H., Anderson, K., Rai, K., Cuttner, J., Yates, J., DuPre,
E., & Holland, J. (1989). The frequency of long-term remission in
patients with acute myelogenous leukaemia treated with conventional
maintenance chemotherapy: A study of 760 patients with a minimal
follow-up time of 6 years. *British Journal of Haematology*, *71*(2),
189–194.

- Schatzkin, A., Carter, C. L., Green, S. B., Kreger, B. E.,
Splansky, G. L., Anderson, K. M., Helsel, surname, & Kannel, W. B.
(1989). Is alcohol consumption related to breast cancer? Results from
the framingham heart study. *JNCI: Journal of the National Cancer
Institute*, *81*(1), 31–35.

- Wilson, P. W., Christiansen, J. C., Anderson, K. M., & Kannel, W.
B. (1989). Impact of national guidelines for cholesterol risk factor
screening: The framingham offspring study. *JAMA*, *262*(1), 41–44.

- Cupples, L. A., D’Agostino, R. B., Anderson, K., & Kannel, W. B.
(1988). Comparison of baseline and repeated measure covariate techniques
in the framingham heart study. *Statistics in Medicine*, *7*(1-2),
205–218.

- Levy, D., Anderson, K. M., Savage, D. D., Kannel, W. B.,
Christiansen, J. C., & Castelli, W. P. (1988). Echocardiographically
detected left ventricular hypertrophy: Prevalence and risk factors: The
framingham heart study. *Annals of Internal Medicine*, *108*(1), 7–13.

- Anderson, K. M., Castelli, W. P., & Levy, D. (1987). Cholesterol
and mortality: 30 years of follow-up from the framingham study. *JAMA*,
*257*(16), 2176–2180.

- Anderson, K. M., Wilson, P. W., Garrison, R. J., & Castelli, W. P.
(1987). Longitudinal and secular trends in lipoprotein cholesterol
measurements in a general population sample the framingham offspring
study. *Atherosclerosis*, *68*(1-2), 59–66.

- Kannel, W. B., Anderson, K., McGee, D. L., Degatano, L. S., &
Stampfer, M. J. (1987). Nonspecific electrocardiographic abnormality as
a predictor of coronary heart disease: The framingham study. *American
Heart Journal*, *113*(2), 370–376.

- Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel,
W. B., & Castelli, W. P. (1987). Echocardiographic criteria for left
ventricular hypertrophy: The framingham heart study. *The American
Journal of Cardiology*, *59*(9), 956–960.

- Levy, D., Anderson, K. M., Plehn, J., Savage, D. D., Christiansen,
J. C., & Castelli, W. P. (1987). Echocardiographically determined left
ventricular structural and functional correlates of complex or frequent
ventricular arrhythmias on one-hour ambulatory electrocardiographic
monitoring. *The American Journal of Cardiology*, *59*(8), 836–840.

- Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel, W.
B., & Castelli, W. P. (1987). Risk of ventricular arrhythmias in left
ventricular hypertrophy: The framingham heart study. *The American
Journal of Cardiology*, *60*(7), 560–565.

- Castelli, W. P., & Anderson, K. (1986). A population at risk:
Prevalence of high cholesterol levels in hypertensive patients in the
framingham study. *The American Journal of Medicine*, *80*(2), 23–32.

- Wilson, P. W., Anderson, K. M., & Kannel, W. B. (1986).
Epidemiology of diabetes mellitus in the elderly: The framingham study.
*The American Journal of Medicine*, *80*(5), 3–9.

- Sobol, R., Royston, I., LeBien, T., Minowada, J., Anderson, K.,
Davey, F., Cuttner, J., Schiffer, C., Ellison, R., & Bloomfield, C.
(1985). Adult acute lymphoblastic leukemia phenotypes defined by
monoclonal antibodies. *Blood*, *65*(3), 730–735.

- Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., & Lee, J.
E. (1985). Early precursors of site-specific cancers in college men and
women. *Journal of the National Cancer Institute*, *74*(1), 43–51.

- Wilson, P., Kannel, W., & Anderson, K. (1985). Lipids, glucose
intolerance and vascular disease: The framingham study. *Monographs on
Atherosclerosis*, *13*, 1–11.

- Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., & Lee, J.
E. (1984). Early precursors of urogenital cancers in former college men.
*The Journal of Urology*, *132*(6), 1256–1261.

- Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., & Halpern,
J. (1983). Early precursors of pancreatic cancer in college men.
*Journal of Chronic Diseases*, *36*(3), 251–256.
